Dee Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.39 M
- Company Age 27 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.80 M
- Revenue Growth 4.45%
- Profit Growth 70.71%
- Ebitda 1136.92%
- Net Worth -0.81%
- Total Assets 96.11%
About Dee Drugs
Dee Drugs Private Limited (DDPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 August 1997 and has a history of 27 years and five months. Its registered office is in Jaipur, Rajasthan.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.39 M.
The company currently has active open charges totaling ₹0.80 M.
Rajesh Gupta and Madhu Gupta serve as directors at the Company.
Company Details
- Location Jaipur, Rajasthan
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232RJ1997PTC014144
-
Company No.
014144
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
21 Aug 1997
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Dee Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Gupta
|
Director | 21-Aug-1997 | Current |
|
Madhu Gupta
|
Director | 21-Aug-1997 | Current |
Financial Performance of Dee Drugs.
Dee Drugs Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.45% increase. The company also saw a substantial improvement in profitability, with a 70.71% increase in profit. The company's net worth dipped by a decrease of 0.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dee Drugs?
Unlock access to Dee Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Maxcare Drugs Private LimitedRajesh Gupta is a mutual person
Charges (Loans)
₹0.80 M
₹0
Charges Breakdown by Lending Institutions
- The Bank Of Rajasthan Limited : 0.08 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 May 1999 | The Bank Of Rajasthan Limited | ₹0.40 M | Open |
| 01 May 1999 | The Bank Of Rajasthan Limited | ₹0.40 M | Open |
How Many Employees Work at Dee Drugs?
Unlock and access historical data on people associated with Dee Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dee Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dee Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.